Xiangxue Pharmaceutical Cash Flow Reinvestment Rate
Xiangxue Pharmaceutical cash flow reinvestment rate. Xiangxue Pharmaceutical (300147) has a Cash Flow Reinvestment Rate of 0.08x as of September 2025, reinvesting CN¥5.74 Million (capex CN¥5.74 Million ) from operating cash flow of CN¥75.64 Million. Explore Xiangxue Pharmaceutical cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Xiangxue Pharmaceutical (2007–2025)
Cash flow reinvestment rate of Xiangxue Pharmaceutical from 2007 to 2025. Historical reinvestment intensity for Xiangxue Pharmaceutical across 19 annual periods. Explore capital reinvestment ratio of Xiangxue Pharmaceutical to see what proportion of operating cash flow is directed to capital expenditures.
Xiangxue Pharmaceutical Cash Flow Reinvestment Rate by Year (2007–2025)
Xiangxue Pharmaceutical cash flow reinvestment rate by year from 2007 to 2025. Year-by-year capital reinvestment analysis for Xiangxue Pharmaceutical. For the full cash flow conversion analysis, see cash efficiency ratio of Xiangxue Pharmaceutical.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.18x | CN¥25.47 Million | CN¥139.63 Million | CN¥21.51 Million | ▼ -94.4% |
| 2024 | 3.24x | CN¥58.95 Million | CN¥18.17 Million | CN¥35.24 Million | ▲ +678.9% |
| 2023 | 0.42x | CN¥109.69 Million | CN¥263.44 Million | CN¥56.03 Million | ▼ -77.7% |
| 2022 | 1.87x | CN¥425.18 Million | CN¥227.38 Million | CN¥367.27 Million | ▼ -21.2% |
| 2021 | 2.37x | CN¥611.43 Million | CN¥257.56 Million | CN¥562.74 Million | ▼ -15.2% |
| 2020 | 2.80x | CN¥719.65 Million | CN¥257.18 Million | CN¥707.42 Million | ▼ -77.3% |
| 2019 | 12.34x | CN¥1.02 Billion | CN¥83.02 Million | CN¥661.09 Million | ▲ +82.4% |
| 2018 | 6.76x | CN¥617.05 Million | CN¥91.24 Million | CN¥495.46 Million | ▼ -19.3% |
| 2017 | 8.38x | CN¥917.76 Million | CN¥109.53 Million | CN¥777.87 Million | ▼ -23.6% |
| 2016 | 10.97x | CN¥2.18 Billion | CN¥198.48 Million | CN¥1.97 Billion | ▲ +183.3% |
| 2015 | 3.87x | CN¥618.83 Million | CN¥159.89 Million | CN¥276.95 Million | ▲ +162.8% |
| 2014 | 1.47x | CN¥243.85 Million | CN¥165.58 Million | CN¥243.85 Million | ▲ +51.8% |
| 2013 | 0.97x | CN¥318.55 Million | CN¥328.37 Million | CN¥318.55 Million | ▼ -72.4% |
| 2012 | 3.52x | CN¥418.12 Million | CN¥118.91 Million | CN¥418.12 Million | ▼ -55.0% |
| 2011 | 7.81x | CN¥230.69 Million | CN¥29.55 Million | CN¥230.69 Million | ▲ +524.1% |
| 2010 | 1.25x | CN¥56.87 Million | CN¥45.47 Million | CN¥56.87 Million | ▲ +9.3% |
| 2009 | 1.14x | CN¥52.86 Million | CN¥46.19 Million | CN¥52.86 Million | ▼ -53.7% |
| 2008 | 2.47x | CN¥137.71 Million | CN¥55.72 Million | CN¥137.71 Million | ▲ +135.7% |
| 2007 | 1.05x | CN¥144.73 Million | CN¥138.02 Million | CN¥144.73 Million | — |